Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Injection Schedule Flexibility on Patient Satisfaction with Botulinum Toxin Treatment for Cervical Dystonia
Movement Disorders
P16 - Poster Session 16 (5:30 PM-6:30 PM)
3-005

Assess the impact of fixed or flexible injection schedules on outcomes in patients receiving abobotulinumtoxinA (aboBoNT-A) for cervical dystonia (CD) in routine practice.

Primary analyses of the INTEREST IN CD2 study indicated that patients with shorter treatment intervals are less likely to be satisfied with their symptom control than those with longer intervals. In routine practice, BoNT-A clinics are often run according to fixed or flexible injection intervals.

INTEREST IN CD2 (NCT01753349) was a 3-year observational study following people with CD treated with BoNT-A. A survey was sent to study sites to ascertain whether they reinjected according to: fixed re-injection intervals (hospital rules/usual practice), a flexible schedule (depending on patient needs) or a mix of both. Satisfaction outcomes (primary outcome measure) for subjects using aboBoNT-A were reanalysed by subgroup.
61 of 113 active sites completed the survey, allowing post-hoc analysis for 337 subjects treated with aboBoNT-A. Of these, 26 subjects (7.7%) were treated according to fixed schedules (median aboBoNT-A dose: 414U, median interval: 14.1 weeks), 141 (41.8%) had flexible schedules (dose: 500U, interval: 15.3 weeks) and 170 (50.4%) had mixed schedules (dose: 525U, interval: 15.9 weeks). While rates of satisfaction at peak effect were similar between groups (satisfaction rates of 89.1%-100%), satisfaction at end of treatment cycle (i.e. at waning of effect) appeared higher for subjects with schedule flexibility (52.2% of subjects with flexible schedules & 52.4% with mixed schedules were satisfied at end of cycle) versus those with fixed schedules (26.9% subjects reported satisfaction).

Subjects with flexibility in their aboBoNT-A injection schedules to meet patient needs had injection intervals of 15.3 weeks. This injection interval was longer than for the fixed schedule group (limited in sample size) and, in line with the primary analysis, was associated with better patient satisfaction even at the end of an injection cycle.
Authors/Disclosures
Vivay Peter Misra, MD
PRESENTER 		No disclosure on file
No disclosure on file
Carlo Colosimo, MD (Universita La Sapienza) No disclosure on file
No disclosure on file
Pascal Maisonobe Pascal Maisonobe has received personal compensation for serving as an employee of ipsen pharma. Pascal Maisonobe has received personal compensation for serving as an employee of Ipsen.
Savary Om No disclosure on file